242 related articles for article (PubMed ID: 6644761)
1. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
[TBL] [Abstract][Full Text] [Related]
2. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai Y; Taga J; Ishizaki T; Ishikawa K
Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
4. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
Eichelbaum M; Bertilsson L; Säwe J
Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
[TBL] [Abstract][Full Text] [Related]
6. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
Meyer UA; Skoda RC; Zanger UM
Pharmacol Ther; 1990; 46(2):297-308. PubMed ID: 2181495
[TBL] [Abstract][Full Text] [Related]
7. Deficient metabolism of debrisoquine and sparteine.
Inaba T; Otton SV; Kalow W
Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
[TBL] [Abstract][Full Text] [Related]
8. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacogenetics of sparteine and debrisoquine.
Inaba T; Vinks A; Otton SV; Kalow W
Clin Pharmacol Ther; 1983 Mar; 33(3):394-9. PubMed ID: 6825393
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
[TBL] [Abstract][Full Text] [Related]
11. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
Eichelbaum M; Gross AS
Pharmacol Ther; 1990; 46(3):377-94. PubMed ID: 2188269
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
Lennard MS
Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
[TBL] [Abstract][Full Text] [Related]
13. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic oxidation of debrisoquine and sparteine.
Eichelbaum M
Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
[No Abstract] [Full Text] [Related]
15. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
Woolhouse NM
Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
[No Abstract] [Full Text] [Related]
16. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
Broly F; Vandamme N; Libersa C; Lhermitte M
Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
[TBL] [Abstract][Full Text] [Related]
17. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
Fonne-Pfister R; Meyer UA
Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.
Gross AS; Mikus G; Fischer C; Hertrampf R; Gundert-Remy U; Eichelbaum M
Br J Clin Pharmacol; 1989 Nov; 28(5):555-66. PubMed ID: 2511912
[TBL] [Abstract][Full Text] [Related]
19. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
Sindrup SH; Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF
Pain; 1993 Jun; 53(3):335-339. PubMed ID: 8351162
[TBL] [Abstract][Full Text] [Related]
20. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Eur J Clin Pharmacol; 1997; 51(5):389-93. PubMed ID: 9049580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]